Health Care • Biotechnology: Pharmaceutical Preparations
$16.78 ▼ -0.42
(-2.44%)
MKT CAP: $1.65B • VOL: 2.80M
52W L $13 52W H $40
RARE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $673.0M | $560.0M | $434.0M |
| YoY Revenue Growth % | +20.2% | +29.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$535.0M | -$536.0M | -$569.0M |
| Operating Margin % | -79.5% | -80.0% | -80.0% |
| Net Income (GAAP) | -$575.0M | -$569.0M | -$607.0M |
| EBITDA (Normalized) | -$530.2M | -$530.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$466.0M | -$414.0M | -$475.0M |
| Capital Expenditures (CapEx) | $6.0M | $7.0M | — |
| Free Cash Flow (FCF) | -$472.0M | -$421.0M | -$475.0M |
| FCF Margin % | -70.1% | -75.2% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $421.0M | $174.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$80.0M | $255.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RARE.